ORPHA:294016
Microcephaly-capillary malformation syndrome
Also known as: MIC-CAP syndrome · MIC-CM syndrome · Microcephaly-cutaneous capillary malformation syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
57
48.5th percentile
Trials
0
Interventional, condition-specific
Researchers
315
Distinct authors in sample
Gene link
STAMBP
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Microcephaly-capillary syndrome is a rare, genetic vascular anomaly characterized by severe microcephaly, poor somatic growth, diffuse multiple capillary malformations on the skin, intractable , profound global , spastic quadriparesis and hypoplastic distal phalanges.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013659
- OMIM:614261
- UMLS:C3280296
Additional Mondo synonyms (2)
microcephaly-capillary malformation syndrome · microcephaly-cutaneous capillary malformation syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — STAMBP
- LiteraturePresent
57 matched papers (38 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (STAMBP).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
57
57 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
57 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
38 in the last 10 years · high confidence · 48.5th percentile (publications denominator)
Phrase hits: 57 · MeSH hits: 0
Who's working on it?
315
Distinct author names in 57 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Boycott KM5 papers · 2022
Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada. Electronic address: kboycott@cheo.on.ca.
Papers in Europe PMC - 02Carter MT5 papers · 2022
Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada. mcarter@hollandbloorview.ca
Papers in Europe PMC - 03Das C4 papers · 2021
Department of Chemistry, Purdue University , 560 Oval Drive, West Lafayette, Indiana 47907, United States.
Papers in Europe PMC - 04Graham JM Jr3 papers · 2022
Medical Genetics, Department of Pediatrics, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Papers in Europe PMC - 05Li H3 papers · 2024
BGI-Anhui Clinical Laboratory, BGI-Shenzhen, 236000, Fuyang, China.
Papers in Europe PMC - 06Liu Y3 papers · 2024
Department of Genetics, Jiangxi Maternal and Child Health Hospital, 330006, Nanchang, China.
Papers in Europe PMC - 07Paul LN3 papers · 2015
Bindley Biosciences Center, Purdue University , West Lafayette, Indiana 47907, United States.
Papers in Europe PMC - 08Xu X3 papers · 2024
Center for Translational Medicine, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China; Department of Ultrasound, The Affiliated Zhangjiagang Hospital of Soochow University, 68 Jiyang West Road, Suzhou, 215600, China.
Papers in Europe PMC - 09Davies CW2 papers · 2014
Department of Chemistry, Purdue University , West Lafayette, Indiana 47907, United States.
Papers in Europe PMC - 10Deng J2 papers · 2024
Department of Child Health Care, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Microcephaly-capillary malformation syndrome" OR "MIC-CAP syndrome" OR "MIC-CM syndrome" OR "Microcephaly-cutaneous capillary malformation syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Microcephaly-capillary malformation syndrome" OR "MIC-CAP syndrome" OR "MIC-CM syndrome" OR "Microcephaly-cutaneous capillary malformation syndrome" OR "STAMBP"
Recall-expansion terms: STAMBP
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:26:13.794Z